Results 191 to 200 of about 17,718 (201)

Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration

Ophthalmology, 2013
Allen C Ho
exaly  

Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

Ophthalmology, 2014
Allen C Ho
exaly  

Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

Ophthalmology, 2011
Michael J Elman, Jennifer K Sun
exaly  

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2019
Peter A Campochiaro, Carl Regillo, Giulio Barteselli   +2 more
exaly  

Ranibizumab

Drugs of the Future, 2003
null Sorbera, L.A., null Leeson, P.A., null Bayes, M.   +2 more
openaire   +1 more source

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

Angiogenesis, 2012
exaly  

Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study

Ophthalmology, 2011
Peter A Campochiaro, Allen C Ho
exaly  

Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study

Ophthalmology, 2010
Quan Dong Nguyen, Thomas A Ciulla
exaly  

Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema

Ophthalmology, 2014
Ursula M Schmidt-Erfurth, Frank G Holz, Paolo Lanzetta   +2 more
exaly  

Ranibizumab

Reactions Weekly, 2018
openaire   +1 more source